186 related articles for article (PubMed ID: 19327923)
1. The LIBERATE tibolone trial in breast cancer survivors.
Speroff L
Maturitas; 2009 May; 63(1):1-3. PubMed ID: 19327923
[No Abstract] [Full Text] [Related]
2. Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials.
Biglia N; Maffei S; Lello S; Nappi RE
Gynecol Endocrinol; 2010 Nov; 26(11):804-14. PubMed ID: 20586550
[TBL] [Abstract][Full Text] [Related]
3. Tibolone revisited: still a good treatment option for healthy, early postmenopausal women.
Kenemans P
Gynecol Endocrinol; 2010 Apr; 26(4):237-9. PubMed ID: 20017707
[No Abstract] [Full Text] [Related]
4. [Hormone therapy and risk for breast cancer in Finnish postmenopausal women].
Lyytinen H; Ylikorkala O
Duodecim; 2011; 127(3):235-42. PubMed ID: 21438346
[TBL] [Abstract][Full Text] [Related]
5. Progestins and recurrence in breast cancer survivors.
Chlebowski RT; Anderson GL
J Natl Cancer Inst; 2005 Apr; 97(7):471-2. PubMed ID: 15812065
[No Abstract] [Full Text] [Related]
6. What have we really learned from 'LIBERATE' trial?
Dimitrakakis C; Tsigginou A; Keramopoulos D; Antsaklis A
Maturitas; 2010 May; 66(1):99-100. PubMed ID: 20236777
[TBL] [Abstract][Full Text] [Related]
7. Tibolone and breast cancer risk: effects of selection bias cannot be eliminated in observational studies.
Coomarasamy A
BJOG; 2008 Jun; 115(7):919. PubMed ID: 18485174
[No Abstract] [Full Text] [Related]
8. A case report of recurrent endometriosis following Tibolone hormone replacement therapy.
Sundar SS; Gornall RJ; Kerr-Wilson R; Swingler GR; Kinder RB; McCarthy K
J Obstet Gynaecol; 2007 May; 27(4):433-4. PubMed ID: 17654209
[No Abstract] [Full Text] [Related]
9. Some comments on the Million Women Study.
Neves-E-Castro M
Climacteric; 2003 Dec; 6(4):357. PubMed ID: 15006258
[No Abstract] [Full Text] [Related]
10. Tibolone: the way to beat many a postmenopausal ailments.
Lazovic G; Radivojevic U; Marinkovic J
Expert Opin Pharmacother; 2008 Apr; 9(6):1039-47. PubMed ID: 18377345
[TBL] [Abstract][Full Text] [Related]
11. The need for tissue selective menopausal agents.
Eden J
Gynecol Endocrinol; 2005 Jul; 21 Suppl 1():22-7. PubMed ID: 16112952
[TBL] [Abstract][Full Text] [Related]
12. Endometrial cancer--surprising reports.
Speroff L
Maturitas; 2005 Aug; 51(4):329-33. PubMed ID: 16039404
[No Abstract] [Full Text] [Related]
13. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group.
Kenemans P; Speroff L;
Maturitas; 2005 May; 51(1):21-8. PubMed ID: 15883105
[TBL] [Abstract][Full Text] [Related]
14. Endometrial adenocarcinoma after prolonged tibolone therapy.
Nassar AH; Khalil AM; Seoud MA; Usta IM
Int J Gynaecol Obstet; 2005 Jul; 90(1):78-9. PubMed ID: 15913616
[No Abstract] [Full Text] [Related]
15. Tibolone.
Reynir Tomas G
Acta Obstet Gynecol Scand; 2004 Jun; 83(6):606. PubMed ID: 15144349
[No Abstract] [Full Text] [Related]
16. Hormone replacement therapy for breast cancer survivors: an answered question?
Zielinski SL
J Natl Cancer Inst; 2005 Jul; 97(13):955. PubMed ID: 15998945
[No Abstract] [Full Text] [Related]
17. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
Eilertsen AL; Liestøl S; Mowinckel MC; Hemker HC; Sandset PM
Thromb Haemost; 2007 Jun; 97(6):938-43. PubMed ID: 17549295
[TBL] [Abstract][Full Text] [Related]
18. [Relation between hormonal therapy and tibolone with SERMs in postmenopausal women's myomes growth].
Carranza Lira S
Ginecol Obstet Mex; 2008 Oct; 76(10):610-4. PubMed ID: 19062511
[TBL] [Abstract][Full Text] [Related]
19. Tibolone and breast cancer.
Prescrire Int; 2010 Dec; 19(111):281. PubMed ID: 21355381
[TBL] [Abstract][Full Text] [Related]
20. Re: Estrogen plus progestin therapy and breast cancer in recently postmenopausal women.
Langer RD
Am J Epidemiol; 2009 Mar; 169(6):784-5; author reply 785-6. PubMed ID: 19208722
[No Abstract] [Full Text] [Related]
[Next] [New Search]
